Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India 'refuses' to progress Novartis Galvumet patent application

This article was originally published in Scrip

Executive Summary

The Indian patent office has declined to "proceed further" with Novartis' application for vildagliptin and metformin in a single formulation (Galvumet) citing lack of inventive step and objections around the "sufficiency of disclosure".

You may also be interested in...



Final Salvo? Galvus Infringement Case Simmers In India

Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.

Pricing Tensions Escalate In India; Novartis Under A Cloud

Charges of price collusion pertaining to Novartis’ Galvus are the latest in a string of allegations that have rocked the pharmaceutical industry in India over the recent past, though the company claims it has not flouted the law. Industry is also under fire for ‘suspected’ deviations from mandated price caps for over 600 medicines – a charge seen widening the trust deficit.

Novartis Galvus India Case: Wockhardt Pulls Back?

Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.

Topics

Related Companies

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel